About the Authors
- Laura Ciarloni
-
Affiliations Diagnoplex SA, Epalinges, Switzerland, Novigenix SA, Epalinges, Switzerland
- Sahar Hosseinian
-
Affiliations Diagnoplex SA, Epalinges, Switzerland, Novigenix SA, Epalinges, Switzerland
- Sylvain Monnier-Benoit
-
Affiliations Diagnoplex SA, Epalinges, Switzerland, Novigenix SA, Epalinges, Switzerland
- Natsuko Imaizumi
-
Current address: Medtronic, Tolochenaz, Switzerland
Affiliations Diagnoplex SA, Epalinges, Switzerland, National Center for Competence in Research (NCCR), Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC)-Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Gian Dorta
-
Affiliation Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland
- Curzio Ruegg
-
* E-mail: curzio.ruegg@unifr.ch
Affiliations Novigenix SA, Epalinges, Switzerland, National Center for Competence in Research (NCCR), Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC)-Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland
- On behalf of the DGNP-COL-0310 Study Group
-
¶Membership of the DGNP-COL-0310 Study Group is provided in the Acknowledgments.
Competing Interests
LC SH SMB NI were employees of Diagnoplex SA at the time of the study. Also, they own stock options in Diagnoplex SA. CR is a co-founder, advisory board member and owns stocks and shares of Diagnoplex SA. GD has served as speaker, consultant and advisory board member for Diagnoplex SA, and has received research funding from Diagnoplex SA. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: LC SH SMB NI GD CR. Performed the experiments: LC SMB SH. Analyzed the data: LC SMB SH. Contributed reagents/materials/analysis tools: SH GD. Wrote the paper: LC SH SMB CR. Writing clinical protocol: NI GD.